Sponsor study identifier
interventional
15
1 country
1
Study Start
January 1, 2024
Actual (reported)Primary Completion
June 11, 2024
Actual (reported)Study Completion
December 31, 2024
Actual (reported)This is a single-site, non-randomized, non-controlled study at UT Southwestern Medical Center at Dallas in the Department of Plastic Surgery. The study is designed to follow up to 15 consenting subjects who may receive up to 2 BBL/MOXI/HALO treatments under an IRB approved protocol.
Registry-reported information. Elapsed time and enrollment totals alone do not measure study progress or recruitment pace.
December 31, 2024
Actual (reported)Click on a node to explore related trials.
Some registry-reported names shown below are not yet linked in this graph.
Dates and qualifiers reported by the registry. Estimated dates do not confirm that a milestone has occurred.
October 13, 2023
Actual (reported)October 19, 2023
Actual (reported)January 1, 2024
Actual (reported)June 11, 2024
Actual (reported)December 31, 2024
Actual (reported)January 27, 2026
Actual (reported)Change in Brown Spots at 1 Month From Baseline (Single Treatment Group)
Quantitively assessment of change in overall UV spots using measurements provided VISIA 3D analysis on different sides of the face for all subjects A lower value signifies improvement
Baseline, 1 Month
Change in Brown Spots at 3 Months From Baseline (Single Treatment Group)
Quantitively assessment of change in overall UV spots using measurements provided VISIA 3D analysis on different sides of the face for all subjects A lower value signifies improvement
Baseline, 3 Months
Change in Brown Spots at 1 Month From Baseline (Double Treatment Group)
Quantitively assessment of change in overall UV spots using measurements provided VISIA 3D analysis on different sides of the face for all subjects A lower value signifies improvement
Baseline, 1 Month
Change in Brown Spots at 3 Months From Baseline (Double Treatment Group)
Quantitively assessment of change in overall UV spots using measurements provided VISIA 3D analysis on different sides of the face for all subjects A lower value signifies improvement
Baseline, 3 Months
Change in Pores at 1 Month From Baseline (Single Treatment Group)
Quantitively assessment of change in overall pore count using measurements provided VISIA 3D analysis on different sides of the face for all subjects A lower value signifies improvement.
Baseline, 1 Month
Change in Pores at 3 Months From Baseline (Single Treatment Group)
Quantitively assessment of change in overall pore count using measurements provided VISIA 3D analysis on different sides of the face for all subjects A lower value signifies improvement.
Baseline, 3 Months
Change in Pores at 1 Month From Baseline (Double Treatment Group)
Quantitively assessment of change in overall pore count using measurements provided VISIA 3D analysis on different sides of the face for all subjects A lower value signifies improvement
Baseline, 1 Month
Change in Pores at 3 Months From Baseline (Double Treatment Group)
Quantitively assessment of change in overall pore count using measurements provided VISIA 3D analysis on different sides of the face for all subjects A lower value signifies improvement.
Baseline, 3 Months
Change in Porphyrins at 1 Month From Baseline (Single Treatment Group)
Quantitively assessment of change in overall porphyrins count using measurements provided VISIA 3D analysis on different sides of the face for all subjects A lower value signifies improvement.
Baseline, 1 Month
Change in Porphyrins at 3 Months From Baseline (Single Treatment Group)
Quantitively assessment of change in overall porphyrins count using measurements provided VISIA 3D analysis on different sides of the face for all subjects A lower value signifies improvement.
Baseline, 3 Months
Change in Porphyrins at 1 Month From Baseline (Double Treatment Group)
Quantitively assessment of change in overall porphyrins count using measurements provided VISIA 3D analysis on different sides of the face for all subjects A lower value signifies improvement.
Baseline, 1 Month
Change in Porphyrins at 3 Months From Baseline (Double Treatment Group)
Quantitively assessment of change in overall porphyrins count using measurements provided VISIA 3D analysis on different sides of the face for all subjects A lower value signifies improvement.
Baseline, 3 Months
Change in Red Features at 1 Month From Baseline (Single Treatment Group)
Quantitively assessment of change in overall red features using measurements provided VISIA 3D analysis on different sides of the face for all subjects A lower value signifies improvement
Baseline, 1 Month
Change in Red Features at 3 Months From Baseline (Single Treatment Group)
Quantitively assessment of change in overall red features using measurements provided VISIA 3D analysis on different sides of the face for all subjects A lower value signifies improvement
Baseline, 3 Months
Change in Red Features at 1 Month From Baseline (Double Treatment Group)
Quantitively assessment of change in overall red features using measurements provided VISIA 3D analysis on different sides of the face for all subjects A lower value signifies improvement
Baseline, 1 Month
Change in Red Features at 3 Months From Baseline (Double Treatment Group)
Quantitively assessment of change in overall red features using measurements provided VISIA 3D analysis on different sides of the face for all subjects A lower value signifies improvement
Baseline, 3 Months
Change in Texture at 1 Month From Baseline (Single Treatment Group)
Quantitively assessment of change in overall texture using measurements provided VISIA 3D analysis on different sides of the face for all subjects. Skin analysis is performed by the system to generate a numerical roughness count by providing a tally of the feature. A lower value signifies improvement. Minimum and Maximum value does not exist. The value is an Absolute Score derived from the integration of multiple topographical variables; because it measures the intensity of texture rather than a specific length or depth, it has no standard metric unit
Baseline, 1 Month
Change in Texture at 3 Months From Baseline (Single Treatment Group)
Quantitively assessment of change in overall texture using measurements provided VISIA 3D analysis on different sides of the face for all subjects. Skin analysis is performed by the system to generate a numerical roughness count by providing a tally of the feature. A lower value signifies improvement. Minimum and Maximum value does not exist. The value is an Absolute Score derived from the integration of multiple topographical variables; because it measures the intensity of texture rather than a specific length or depth, it has no standard metric unit
Baseline, 3 Months
Change in Texture at 1 Month From Baseline (Double Treatment Group)
Quantitively assessment of change in overall texture using measurements provided VISIA 3D analysis on different sides of the face for all subjects. Skin analysis is performed by the system to generate a numerical roughness count by providing a tally of the feature. A lower value signifies improvement. Minimum and Maximum value does not exist. The value is an Absolute Score derived from the integration of multiple topographical variables; because it measures the intensity of texture rather than a specific length or depth, it has no standard metric unit
Baseline, 1 Month
Change in Texture at 3 Months From Baseline (Double Treatment Group)
Quantitively assessment of change in overall texture using measurements provided VISIA 3D analysis on different sides of the face for all subjects. Skin analysis is performed by the system to generate a numerical roughness count by providing a tally of the feature. A lower value signifies improvement. Minimum and Maximum value does not exist. The value is an Absolute Score derived from the integration of multiple topographical variables; because it measures the intensity of texture rather than a specific length or depth, it has no standard metric unit
Baseline, 3 Months
Change in UV Spots at 1 Month From Baseline (Single Treatment Group)
Quantitively assessment of change in overall UV spots using measurements provided VISIA 3D analysis on different sides of the face for all subjects A lower value signifies improvement
Baseline, 1 Month
Change in UV Spots at 3 Months From Baseline (Single Treatment Group)
Quantitively assessment of change in overall UV spots using measurements provided VISIA 3D analysis on different sides of the face for all subjects A lower value signifies improvement
Baseline, 3 Months
Change in UV Spots at 1 Month From Baseline (Double Treatment Group)
Quantitively assessment of change in overall UV spots using measurements provided VISIA 3D analysis on different sides of the face for all subjects A lower value signifies improvement
Baseline, 1 Month
Change in UV Spots at 3 Months From Baseline (Double Treatment Group)
Quantitively assessment of change in overall UV spots using measurements provided VISIA 3D analysis on different sides of the face for all subjects A lower value signifies improvement
Baseline, 3 Months
Change in Visible Spots at 1 Month From Baseline (Single Treatment Group)
Quantitively assessment of change in overall visible spots using measurements provided VISIA 3D analysis on different sides of the face for all subjects A lower value signifies improvement
Baseline, 1 Month
Change in Visible Spots at 3 Months From Baseline (Single Treatment Group)
Quantitively assessment of change in overall visible spots using measurements provided VISIA 3D analysis on different sides of the face for all subjects A lower value signifies improvement
Baseline, 3 Months
Change in Visible Spots at 1 Month From Baseline (Double Treatment Group)
Quantitively assessment of change in overall visible spots using measurements provided VISIA 3D analysis on different sides of the face for all subjects A lower value signifies improvement
Baseline, 1 Month
Change in Visible Spots at 3 Months From Baseline (Double Treatment Group)
Quantitively assessment of change in overall visible spots using measurements provided VISIA 3D analysis on different sides of the face for all subjects A lower value signifies improvement
Baseline, 3 Months
Change in Total Wrinkle Area at 1 Month From Baseline (Single Treatment Group)
Quantitively assessment of change in overall wrinkle are using measurements provided VISIA 3D analysis on different sides of the face for all subjects A lower value signifies improvement.
Baseline, 1 Month
Change in Total Wrinkle Area at 3 Months From Baseline (Single Treatment Group)
Quantitively assessment of change in overall wrinkle are using measurements provided VISIA 3D analysis on different sides of the face for all subjects A lower value signifies improvement.
Baseline, 3 Months
Change in Total Wrinkle Area at 1 Month From Baseline (Double Treatment Group)
Quantitively assessment of change in overall wrinkle are using measurements provided VISIA 3D analysis on different sides of the face for all subjects A lower value signifies improvement.
Baseline, 1 Month
Change in Total Wrinkle Area at 3 Months From Baseline (Double Treatment Group)
Quantitively assessment of change in overall wrinkle are using measurements provided VISIA 3D analysis on different sides of the face for all subjects A lower value signifies improvement.
Baseline, 3 Months
Subjects will receive a single treatment of BBL/MOXI/HALO
Subjects will receive double treatment of BBL/MOXI/HALO 4-6 weeks apart.
Sciton Joule System
Registry-reported names are shown in full. Names without a link have not yet been matched to a Syfrah profile.
University of Texas Southwestern Medical Center
Dallas, Texas, 75390, United States
Jeffrey Kenkel, MD
UT Southwestern
15 participants (actual enrollment reported by the registry).
First Submitted
October 13, 2023
First Posted
October 19, 2023
Study Start
January 1, 2024
Contact the study team to confirm eligibility.
Primary Completion
June 11, 2024
Actual (reported)Study Completion
December 31, 2024
Actual (reported)Last Updated
January 27, 2026
Results First Posted
January 27, 2026
Record last verified: 2025-11
Download the complete ClinicalTrials.gov record imported by Syfrah, including fields not shown in this page. The registry may contain a newer revision.
Source: ClinicalTrials.gov.
JSON downloads include source attribution and retrieval details alongside the unchanged original record or the separately normalized values.
Source retrieved: